CureVac
180 articles about CureVac
-
Publication In EMBO Molecular Medicine Demonstrates CureVac's Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins And Tumors
8/15/2017
-
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine
7/26/2017
-
CureVac To Receive Patent Claiming The Combination Of mRNA Vaccines With Anti-PD-1 Antibodies
7/20/2017
-
CureVac Expands GMP Production Capacities For RNA Products
6/26/2017
-
CureVac Extends Global Intellectual Property Estate For Prophylactic mRNA Vaccines
6/13/2017
-
CureVac Appoints Daniel Menichella As CEO Of CureVac Inc., The Company's U.S. Subsidiary
5/2/2017
-
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna
1/12/2017
-
Study With CureVac's RNAdjuvant Technology Published In Cancer Immunology, Immunotherapy, Demonstrates Equal Responsiveness Of Blood Cells From Both Hepatocellular Carcinoma (HCC) Patients And Healthy Subjects To The RNA-Based Adjuvant
12/5/2016
-
CureVac Secures An Additional $29.5 Million From Two New Investors
11/9/2016
-
CureVac Receives Broad Patent For RNAntibody Technology
11/9/2016
-
CureVac Appoints Pierre Kemula As Chief Financial Officer
10/11/2016
-
CureVac Release: Study In Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode Of Action Of mRNA Vaccines
7/14/2016
-
CureVac Appoints Leading Experts To Its Scientific Advisory Board
3/30/2016
-
CureVac Strengthens Supervisory Board To Support Global Growth Opportunities And mRNA Product Expansion
3/21/2016
-
CureVac Announces "MERAN" Has Been Approved By The WHO As Suffix For Mrna Drug Substances
2/18/2016
-
CureVac To Present At The 34th Annual J.P. Morgan Healthcare Conference
12/21/2015
-
CureVac Banks $110 Million
11/3/2015
-
CureVac Sets Up Shop in Cambridge, Mass. to Expand mRNA Therapies
9/10/2015
-
IAVI And CureVac Partner To Accelerate Development And Testing Of AIDS Vaccine Candidates
9/9/2015
-
CureVac To Present At BioCentury's 22nd Annual NewsMakers In The Biotech Industry Conference
9/3/2015